Physician Assistant in Hancock, MI Accepting Medicare

7 Physician Assistant nurses found. Showing 1 - 7

Mercedes A Maki, PA Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 500 Campus Dr, Hancock, MI 49930 Phone: 906-483-1000    Fax: 906-483-1103

Ms. Courtney Holly Smith, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 500 Campus Dr, Emergency Department, Hancock, MI 49930 Phone: 906-483-1000

Kathryn E Kass, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 500 Campus Drive, Suite 1, Hancock, MI 49930 Phone: 906-483-1040    Fax: 906-483-1270

Mr. Guy Pellegrini, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 500 Campus Dr, Hancock, MI 49930 Phone: 906-483-1000

Jesse R Primeau, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 500 Campus Dr, Hancock, MI 49930 Phone: 906-483-1777

Whitney J Brey, PA Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 500 Campus Dr, Suite 2, Hancock, MI 49930 Phone: 906-483-1060    Fax: 906-483-1270

Ms. Megan M Brueggeman, PA Physician Assistant - Surgical Medicare: Not Enrolled in Medicare Practice Location: 500 Campus Drive, Suite 1, Hancock, MI 49930 Phone: 906-483-1040    Fax: 906-483-1270

News Archive

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Researchers from Ohio State University have been investigating mutations in the rest of the spike protein, particularly the Q677H mutation.

Limited immune responses three months after Pfizer-BioNTech vaccination among elderly

In this study, published on the medRxiv* preprint server, the humoral response to SARS-CoV-2 was assessed before and after three months of administration of the BNT162b2 mRNA COVID-19 vaccination (Pfizer-BioNTech). In addition, elders' humoral responses were compared to those of a younger group, and a functional neutralization experiment against the Wuhan-Hu-1 (WH1) virus and the Delta variant was carried out.

FDA grants Fast Track designation to Sunesis' vosaroxin for treatment of AML

Sunesis Pharmaceuticals, Inc. today announced that vosaroxin, the Company's lead drug candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration for the potential treatment of relapsed or refractory acute myeloid leukemia in combination with cytarabine.

A global review of factors that influence current diagnosis delay in axSpA

The Axial Spondyloarthritis International Federation (ASIF) set out to coordinate a comprehensive evidence-based global review of the factors influencing the current diagnosis delay in axSpA, and to produce a definitive report that shines a light on these barriers, as well as providing a resource that can ultimately empower a range of international stakeholders to reduce this delay.

Cytomedix secures $13 million in registered direct offering under equity purchase agreements

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today that the Company has secured approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements.

Read more Medical News

› Verified 9 days ago